RecruitingEarly Phase 1NCT07239895

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans


Sponsor

Regend Therapeutics

Enrollment

12 participants

Start Date

Nov 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.


Eligibility

Min Age: 28 DaysMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Airway Basal Stem Cells for people with pediatric bronchiolitis obliterans. The study is currently recruiting participants at 1 location. People eligible for this study include aged 28 Days to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAirway Basal Stem Cells

Airway Basal Stem Cells


Locations(1)

Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07239895